This article is more than 5 years old. Information may no longer be current.
Radiation between chemotherapy cycles efficacious in uterine papillary serous carcinoma
Click Here to Manage Email Alerts
42nd Annual Meeting of the Society for Gynecologic Oncologists
ORLANDO — Radiation therapy “sandwiched” between cycles of carboplatin and paclitaxel was well-tolerated and efficacious in women with completely resected uterine papillary serous carcinoma, according to data from a phase 2 study.
“This sequential administration of chemotherapy and radiation therapy as opposed to concomitant allows for maximum therapeutic benefit of both with less toxicity,” said Mark Einstein, MD, of the Albert Einstein College of Medicine/Montefiore Medical Center in Bronx, N.Y. “This regimen should be considered as an arm for future phase 3 clinical trials in patients with uterine papillary serous carcinoma.”
Einstein and colleagues conducted the study, which included 78 women with uterine papillary serous carcinoma that had been completely resected. The women were all treated at a single institution between 1999 and 2010.
The patients received carboplatin plus paclitaxel every 21 days. After they received three doses, the women then received radiation therapy in the form of brachytherapy, external beam radiation therapy or both. They then received three additional cycles of carboplatin plus paclitaxel.
The median age of the patients was 68 years, and 82% of the women had disease confined to uterus and were classified as stage I or stage II. Most of the patients (83%) completed the prescribed therapy. All patients had radiation therapy regardless of the number of chemotherapy cycles they completed. Most of the patients (84.6%) had brachytherapy and external beam radiation therapy.
There were follow-up data available for 72 women. For the patients with stage I or stage II disease, the PFS was 48.5 months and the OS was 47.6 months. For patients with stage III or stage IV disease, the PFS was 24.1 months and the OS was 34 months.
A total of 435 chemotherapy cycles were given, and for 63 of the cycles, grade-3 hematologic toxicity was present. For 56 cycles, grade-4 hematologic toxicity was present. There were 11 grade-3 or grade-4 non-hematologic toxicities, including infection and deep vein thrombosis.
For more information:
- Einstein M. #21. Presented at: 42nd Annual Meeting of the Society of Gynecologic Oncologists; March 6-9, 2011; Orlando, Fla.
Disclosure: The researchers report no relevant financial disclosures.
 |
Follow HemOncToday.com on Twitter. |